Alzheimer’s treatment thrills investors as doctors debate effect
Wall Street wants to know if physicians will prescribe the Eisai and Biogen drug
In a press release in late September announcing that Eisai’s experimental Alzheimer’s drug had significantly slowed progression of the memory-robbing disease, the company’s chief executive officer, Haruo Naito, was anything but circumspect. The results from the late-stage study, he said, “prove the amyloid hypothesis."
Login to enjoy exclusive benefits!
- Unlocked premium articles
- Personalized news
- Market Watchlist
- Insightful Newsletters & more